[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N: Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr; 2004 May-Jun;216(3):132-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to the National Wilms Tumor Study Group (NWTSG) the SIOP trials and studies largely focus on the issue of preoperative therapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible.
  • PATIENTS AND METHODS: In the SIOP 93-01/GPOH trial and study 1 020 patients with a newly diagnosed renal tumor were registered.
  • 847 of them had a histological proven Wilms Tumor, of whom 637 were unilateral localized, and 173 tumors had an other histology [40 congenital mesoblastic nephroma (CMN), 51 clear cell sarcoma (CCSK), 24 rhabdoid tumor (RTK) and 58 other tumors].
  • The main objective of the trial was the randomized question, if the postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia can be reduced from conventional 3 courses to an experimental 1 course without loss of efficacy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / mortality. Nephroma, Mesoblastic / pathology. Nephroma, Mesoblastic / surgery. Prognosis. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / pathology. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175957.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


2. Radulescu VC, Gerrard M, Moertel C, Grundy PE, Mathias L, Feusner J, Diller L, Dome JS: Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer; 2008 Feb;50(2):246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis.
  • BACKGROUND: Clear cell sarcoma of the kidney (CCSK) is known for its propensity to metastasize to bone, but it also spreads to other sites including the brain.
  • This study was undertaken to describe the treatment and outcomes of patients with recurrent CCSK involving the brain.
  • METHODS: A retrospective records review was conducted on eight patients with CCSK who developed brain metastases after complete responses to initial therapy.
  • RESULTS: The recurrences occurred at a median of 24.5 months after initial diagnosis (range, 12-53 months).
  • All patients received a variable number of courses of ifosfamide, carboplatin, and etoposide (ICE), with or without other agents.
  • Four patients received high-dose chemotherapy with autologous stem cell rescue.
  • Three survivors received high-dose chemotherapy with stem cell rescue.
  • CONCLUSION: Patients with recurrent CCSK involving the brain can have durable survival after recurrence.
  • ICE chemotherapy, together with radiation therapy and surgery, provides a reasonable salvage regimen for recurrent CCSK.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Kidney Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Sarcoma, Clear Cell / secondary. Sarcoma, Clear Cell / therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17226850.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Brownlee NA, Hazen-Martin DJ, Garvin AJ, Re GG: Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma. Pediatr Dev Pathol; 2002 May-Jun;5(3):257-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.
  • Mutation of p53 has been implicated in progression of classical Wilms tumor (WT) into the anaplastic variant (AWT), drug resistance, and poor prognosis.
  • Because of prognostic similarities, clear cell sarcoma of the kidney (CCSK) has been classified with AWT and other aggressive pediatric renal tumors, apart from congenital mesoblastic nephroma (CMN), which is instead a relatively benign tumor of neonates.
  • Initially, CCSK and CMN were assumed to be ontologically related, but the role of p53 in the pathogenesis of either disease has not been sufficiently evaluated as in AWT.
  • We examined the status of p53 in CMN and CCSK in comparison to AWT by immunohistochemistry and mRNA analysis of p53, the downstream effector p21(WAF-1/CIP-1) ( p21), the multidrug resistance gene MDR-1, a putative target of p53, and the p53-antagonist Mdm-2.
  • Surprisingly, strong p53 nuclear immunoreactivity was found in cultures from two CMN specimens, but not in frozen or fixed tumor tissue from five other CMN specimens, nor in cell lines or tumor tissue from CCSK.
  • The size of the p53 mRNA in CMN and CCSK primary tumors excluded gross deletions or rearrangements.
  • Low levels of Mdm-2 mRNA in CCSK and CMN primary tumors and cultures did not support a role for Mdm-2.
  • Absence of MDR-1 mRNA excluded MDR-1 in the drug-resistant phenotype of CCSK.
  • Cisplatin-induced p21 transactivation assays and G(1) cell cycle arrest analyses showed that p21 transactivation and G(1) arrest occurred in both CCSK and CMN cultures, demonstrating integrity of the p53 signal transduction pathway.
  • Absence of p53 functional abnormalities excluded relationships between CCSK and CMN as in AWT, supporting the association of cellular CMN with congenital fibrosarcomas as more recently proposed.
  • [MeSH-major] Gene Expression Profiling. Kidney Neoplasms / metabolism. Nephroma, Mesoblastic / metabolism. Nuclear Proteins. Sarcoma, Clear Cell / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p21. Cyclins / genetics. Cyclins / metabolism. DNA, Neoplasm / analysis. Humans. Immunoenzyme Techniques. Infant, Newborn. Neoplasm Staging. P-Glycoprotein / genetics. P-Glycoprotein / metabolism. Phenotype. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-mdm2. RNA, Messenger / metabolism. Signal Transduction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Congenital Mesoblastic Nephroma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12007018.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-42326
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / DNA, Neoplasm; 0 / Nuclear Proteins; 0 / P-Glycoprotein; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


Advertisement
4. Stefanowicz J, Sierota D, Balcerska A, Stoba C: [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report]. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):197-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Wilms' tumour is the most common primary renal tumour of childhood.
  • Among these 2 cases of nephroblastoma with diffuse anaplasia, 6 with sarcomatous stroma and 2 cases with clear cell sarcoma of the kidney were diagnosed.
  • The staging stratification was as follows: stage I-l, II N (-)-l, II N (+) -3, III- 6, including a neoplasmic occluding thrombus in the inferior vena cava, IV - 0, V-0.
  • In the analysed group there were no patients with stage IV disease, no relapses were observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Carcinosarcoma / drug therapy. Carcinosarcoma / pathology. Child. Child, Preschool. Dactinomycin / administration & dosage. Female. Humans. Infant. Male. Neoplasm Staging. Poland. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / pathology. Survival Analysis. Time Factors. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738594.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; SIOP protocol
  •  go-up   go-down


5. Hempel L, Sauerbrey A, Zintl F, Weirich A, Lemmer A, Graf N: Successful management of a child with clear cell sarcoma of the kidney (CCSK) and multifocal bone metastases at diagnosis. Med Pediatr Oncol; 2003 Jul;41(1):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful management of a child with clear cell sarcoma of the kidney (CCSK) and multifocal bone metastases at diagnosis.
  • [MeSH-major] Bone Neoplasms / therapy. Kidney Neoplasms / therapy. Sarcoma, Clear Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Combined Modality Therapy. Dactinomycin / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Female. Hematopoietic Stem Cell Mobilization. Humans. Radiotherapy, Adjuvant. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12764765.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; SIOP protocol
  •  go-up   go-down


6. Little SE, Bax DA, Rodriguez-Pinilla M, Natrajan R, Messahel B, Pritchard-Jones K, Vujanic GM, Reis-Filho JS, Jones C: Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4360-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney.
  • We sought to evaluate these variables in pediatric renal tumors.
  • EXPERIMENTAL DESIGN: We screened a series of 307 pediatric renal tumors for EGFR expression by immunohistochemistry and gene amplification by chromogenic in situ hybridization.
  • In identifying a striking predilection for certain tumor types, we further analyzed the clear cell sarcomas of the kidney (CCSK) for mutations in EGFR and PTEN.
  • Identification of factors predictive of poor response to targeted therapy, including the drug resistance T790M mutation, may provide a rationale for upfront trials with irreversible inhibitors of EGFR in children with these tumors.
  • [MeSH-major] Kidney Neoplasms / metabolism. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / metabolism. Sarcoma, Clear Cell / metabolism. Signal Transduction
  • [MeSH-minor] Child, Preschool. Gene Amplification. Humans. Immunoenzyme Techniques. In Situ Hybridization. Infant. Mutation. Nephroma, Mesoblastic / metabolism. Nephroma, Mesoblastic / pathology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology. Tissue Array Analysis. Wilms Tumor / metabolism. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646270.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


7. Mitchell C, Jones PM, Kelsey A, Vujanic GM, Marsden B, Shannon R, Gornall P, Owens C, Taylor R, Imeson J, Middleton H, Pritchard J: The treatment of Wilms' tumour: results of the United Kingdom Children's cancer study group (UKCCSG) second Wilms' tumour study. Br J Cancer; 2000 Sep;83(5):602-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) to improve the outlook for patients with inoperable primary tumours and those patients with stage IV and unfavourable histology disease.
  • The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with anaplastic or rhabdoid variants remains poor.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / surgery. Wilms Tumor / drug therapy. Wilms Tumor / radiotherapy. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / radiotherapy. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / radiotherapy. Sarcoma, Clear Cell / surgery. Time Factors. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Cancer Research Campaign.
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Semin Urol Oncol. 1999 Feb;17(1):28-32 [10073403.001]
  • [Cites] Cancer. 1981 May 1;47(9):2302-11 [6164480.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):270-3 [2838151.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1187-90 [2162911.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):268-73 [1846405.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] BMJ. 1992 Jun 6;304(6840):1491-4 [1611375.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1014-23 [8388918.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):124-33 [7799012.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1546-56 [7602343.001]
  • [Cites] J Natl Cancer Inst Monogr. 1995;(19):21-5 [7577200.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):46-63 [8548525.001]
  • [Cites] Med Pediatr Oncol. 1996 Mar;26(3):147-52 [8544795.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Dec;9(6):1329-39 [8591969.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):150-2 [9722896.001]
  • [Cites] J Urol. 1998 Oct;160(4):1450-3 [9751391.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3744-51 [9850017.001]
  • [Cites] Br Med J. 1979 Sep 8;2(6190):567-9 [227525.001]
  • (PMID = 10944599.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine
  • [Other-IDs] NLM/ PMC2363501
  •  go-up   go-down


8. Grundy RG, Hutton C, Middleton H, Imeson J, Pritchard J, Kelsey A, Marsden HB, Vujanic GM, Taylor RE, United Kingdom Children's Cancer Study Group: Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study. Pediatr Blood Cancer; 2004 Apr;42(4):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six had clear cell sarcoma of the kidney (CCSK) and seven had rhabdoid tumours of the kidney (RTK) and are analysed separately.
  • Ninety-two patients were followed for a median of 115 months.
  • Thirty-three patients had inoperable disease at diagnosis and received pre-nephrectomy chemotherapy.
  • The overall and event-free survival (EFS) of children with stage III CCSK was 100% and was achieved with the majority of patients not receiving radiotherapy (CI: 48-100).
  • The combination of abdominal RT together with 3-drug chemotherapy achieves a high abdominal tumour control rate.
  • The high OS for stage III CCSK on this protocol suggests that treatment duration could be curtailed and the role of RT reviewed, though the numbers are small.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Child. Dactinomycin / therapeutic use. Doxorubicin / therapeutic use. Great Britain. Humans. Radiotherapy, Adjuvant. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / radiotherapy. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14966826.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down






Advertisement